225
associated with boceprevir plus pegylated interferon-alpha2b and ribavirin in
patients with chronic hepatitis C in the SPRINT-1 trial. Antivir Ther 2013; 18:387-397.
14.
Kieffer TL, Kwong AD, Picchio GR. Viral resistance to specifically targeted antiviral
therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother 2010; 65:202-212.
15.
Susser S, Vermehren J, Forestier N ve ark. Analysis of long-term persistence of
resistance mutations within the hepatitis C virus NS3 protease after treatment with
telaprevir or boceprevir. J Clin Virol 2011; 52:321-327.
16.
Lawitz E, Poordad F, Brainard DM ve ark. 2013. Sofosbuvir in combination with
peginterferon and ribavirin for 12weeks provides high SVR rates in HCV-infected
genotype 2 or 3 treatment experienced patients with and without compensated
cirrhosis: results from the LONESTAR-2 study. In: 64th Annual Meeting of the
American Association for the Study of Liver Disease, 1–5 November, 2013,
Washington DC, USA. (Abstract LB-4).
17.
Sulkowski MS, Jacobson IM, Nelson DR. Daclatasvir plus sofosbuvir for HCV
infection. N Engl J Med 2014; 370:1560-1561.
18.
Yalçın S. Akut viral hepatitin tarihçesi. Klimik dergi 1988: 1;4-5.
19.
Aygen B, Keten D, Akalın H, ve ark. Kronik hepatit C virusu infeksiyonunun
yönetimi: Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği Viral Hepatit
Çalışma Grubu Uzlaşı Raporu. Klimik Derg. 2014; 27(Suppl. 1): 19-39.
20.
Hayden FG. Antiviral drugs (other than antiretrovirals). In: MandellLG, Bennett JE,
Dolin R, eds. Mandell, Douglas and Bennetts Principles and Practice of Infectious
Diseases. 5th ed. Philadelphia: Churchill Livingstone, 2000: 460-91.
21.
Sönmez E. Antiviral Direnç Monitorizasyonu ve Klinik Yararı. Klimik Dergisi l Cilt 14,
Sayı:2 l 2001, 66-70.
22.
Pawlotsky JM, Chevaliez S, Mchutchison JG. The hepatitis C virus life cycle as a
target for new antiviral therapies. Gastroenterology 2007; 132:1979-1998.
23.
Demirtürk N. Kronik hepatit C tedavisinde yeni seçenekler. Tıp Derg 2011;21(4): 163-
168.
24.
Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol
2011; 55:192-206.
25.
E. Poveda, V. Soriano Drug resistance testing in hepatitis C therapy Future Virol., 7
(2012), pp. 1-13.
26.
Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis
C virus infection. Gastroenterology 2010; 138:447-462.
27.
Kieffer TL, DE Ms, Bartels DJ ve ark. Hepatitis C viral evolution in genotype 1
treatment-naive and treatment-experienced patients receiving telaprevir-based
therapy in clinical trials. PLoS One 2012; 7:e34372.
28.
Moreno C, Berg T, Tanwandee T ve ark. Antiviral activity of TMC435 monotherapy
in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-
label study. J Hepatol 2012; 56:1247-1253.
29.
Lenz O, Fevery B, Vijgen L, Verbeeck J, Peeters M, Beumont-Mauviel M, Zeuzem
S, Picchio G. TMC435 in patients infected with HCV genotype 1 who have failed
previous pegylated interferon/ribavirin treatment: Virological analysis of the
ASPIRE trial. J Hepatol 2012; 56 Suppl 2: S5.
30.
Manns, M, Vierling, J.M, Bacon, B.R., ve ark., 2013. High sustained viral response
at 12- and 24-week follow-up of MK-5172 with pegylated interferon alfa-2b and
ribavirin in HCV genotype 1 treatment-naïve non-cirrhotic patients. In: 48th Annual
Meeting of the European Association for the Study of the Liver (EASL 2013), 24–28
April, 2013, Amsterdam, Belgium. (Abstract 66).
Antiviral Direnç
